Table 2.
Univariate and multivariate analyses for OS in BTC patients
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
|
|
|
|||
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Type | ||||
|
| ||||
| GBC | Reference | |||
|
| ||||
| ECC | 0.97 (0.74–1.27) | 0.799 | ||
|
| ||||
| ICC | 1.12 (0.81–1.54) | 0.496 | ||
|
| ||||
| Age (yr) | ||||
|
| ||||
| ≤ 60 | Reference | |||
|
| ||||
| > 60 | 1.21 (0.97–1.51) | 0.087 | ||
|
| ||||
| Sex | ||||
|
| ||||
| Female | Reference | |||
|
| ||||
| Male | 0.97 (0.78–1.21) | 0.785 | ||
|
| ||||
| Blood typea) | ||||
|
| ||||
| AB | Reference | |||
|
| ||||
| A | 0.67 (0.42–1.07) | 0.091 | ||
|
| ||||
| B | 0.85 (0.56–1.31) | 0.467 | ||
|
| ||||
| O | 0.85 (0.55–1.32) | 0.467 | ||
|
| ||||
| Fever | ||||
|
| ||||
| No | Reference | |||
|
| ||||
| Yes | 1.02 (0.75–1.39) | 0.902 | ||
|
| ||||
| Emaciation | ||||
|
| ||||
| No | Reference | |||
|
| ||||
| Yes | 1.35 (1.08–1.68) | 0.007b) | ||
|
| ||||
| Debilitation | ||||
|
| ||||
| No | Reference | |||
|
| ||||
| Yes | 1.10 (0.78–1.55) | 0.582 | ||
|
| ||||
| Drink | ||||
|
| ||||
| No | Reference | |||
|
| ||||
| Yes | 0.91 (0.70–1.18) | 0.491 | ||
|
| ||||
| Fat liver | ||||
|
| ||||
| No | Reference | |||
|
| ||||
| Yes | 1.19 (0.80–1.77) | 0.393 | ||
|
| ||||
| ALT (U/L) | ||||
|
| ||||
| ≤ 100 | Reference | |||
|
| ||||
| > 100 | 1.17 (0.94–1.45) | 0.167 | ||
|
| ||||
| AST (U/L) | ||||
|
| ||||
| ≤ 100 | Reference | |||
|
| ||||
| > 100 | 1.17 (0.92–1.48) | 0.198 | ||
|
| ||||
| GGT (U/L) | ||||
|
| ||||
| ≤ 200 | Reference | |||
|
| ||||
| > 200 | 1.23 (0.98–1.53) | 0.073 | ||
|
| ||||
| ALP (U/L) | ||||
|
| ||||
| ≤ 200 | Reference | |||
|
| ||||
| > 200 | 1.40 (1.12–1.75) | 0.003b) | ||
|
| ||||
| ALB (g/L) | ||||
|
| ||||
| ≤ 35 | Reference | |||
|
| ||||
| > 35 | 0.64 (0.50–0.81) | < 0.001b) | ||
|
| ||||
| TBIL (μmol/L) | ||||
|
| ||||
| ≤ 106 | Reference | |||
|
| ||||
| > 106 | 1.61 (1.30–2.01) | < 0.001b) | ||
|
| ||||
| CA19-9 (U/mL) | ||||
|
| ||||
| ≤ 100 | Reference | |||
|
| ||||
| > 100 | 2.01 (1.60–2.53) | < 0.001b) | 1.60 (1.25–2.05) | < 0.001b) |
|
| ||||
| Tumor differentiation | ||||
|
| ||||
| Poor | Reference | |||
|
| ||||
| Moderate | 0.68 (0.47–0.98) | 0.040b) | 0.72 (0.59–0.87) | < 0.001b) |
|
| ||||
| Well | 0.44 (0.30–0.65) | < 0.001b) | ||
|
| ||||
| Radical cure | ||||
|
| ||||
| No | Reference | |||
|
| ||||
| Yes | 0.40 (0.32–0.50) | < 0.001b) | 0.47 (0.37–0.60) | < 0.001b) |
|
| ||||
| T category | ||||
|
| ||||
| Tis | Reference | |||
|
| ||||
| 1 | 5.38 (0.75–38.71) | 0.095 | ||
|
| ||||
| 2 | 6.43 (0.90–46.14) | 0.064 | ||
|
| ||||
| 3 | 9.03 (1.26–64.60) | 0.028a) | ||
|
| ||||
| 4 | 6.07 (0.82–45.13) | 0.078 | ||
|
| ||||
| Nodal involvement | ||||
|
| ||||
| No | Reference | |||
|
| ||||
| Yes | 1.99 (1.58–2.50) | < 0.001b) | 1.68 (1.31–2.15) | < 0.001b) |
|
| ||||
| Tumor size (cm) | ||||
|
| ||||
| ≤ 2.6 | Reference | |||
|
| ||||
| > 2.6 | 0.90 (0.72–1.13) | 0.364 | ||
|
| ||||
| Postoperative chemotherapy | ||||
|
| ||||
| No | Reference | |||
|
| ||||
| Yes | 0.93 (0.71–1.22) | 0.624 | ||
|
| ||||
| MPV (fl) | ||||
|
| ||||
| ≤ 8.1 | Reference | |||
|
| ||||
| > 8.1 | 1.52 (1.19–1.95) | < 0.001b) | 1.33 (1.01–1.75) | 0.045b) |
|
| ||||
| PDW/PCT | ||||
|
| ||||
| ≤ 190 | Reference | |||
|
| ||||
| > 190 | 0.65 (0.52–0.82) | < 0.001b) | 0.78 (0.61–1.00) | 0.046b) |
ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BTC, biliary tract cancer; CA19-9, carbohydrate antigen 19-9; CI, confidence interval; ECC, extrahepatic cholangiocarcinoma; GBC, gallbladder cancer; GGT, γ-glutamyl transpeptidase; HR, hazard ratio; ICC, intrahepatic cholangiocarcinoma; MPV, mean platelet volume; OS, overall survival; PCT, plateletocrit; PDW, platelet distribution width; TBIL, total bilirubin.
a)
All patients were Rh positive,
b)
Statistically significant (p < 0.05).